Correlation Between NextCure and Replimune

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both NextCure and Replimune at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NextCure and Replimune into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between NextCure and Replimune Group, you can compare the effects of market volatilities on NextCure and Replimune and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NextCure with a short position of Replimune. Check out your portfolio center. Please also check ongoing floating volatility patterns of NextCure and Replimune.

Diversification Opportunities for NextCure and Replimune

0.38
  Correlation Coefficient

Weak diversification

The 3 months correlation between NextCure and Replimune is 0.38. Overlapping area represents the amount of risk that can be diversified away by holding NextCure and Replimune Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Replimune Group and NextCure is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NextCure are associated (or correlated) with Replimune. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Replimune Group has no effect on the direction of NextCure i.e., NextCure and Replimune go up and down completely randomly.

Pair Corralation between NextCure and Replimune

Given the investment horizon of 90 days NextCure is expected to under-perform the Replimune. In addition to that, NextCure is 1.12 times more volatile than Replimune Group. It trades about -0.16 of its total potential returns per unit of risk. Replimune Group is currently generating about -0.05 per unit of volatility. If you would invest  1,233  in Replimune Group on December 30, 2024 and sell it today you would lose (194.00) from holding Replimune Group or give up 15.73% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

NextCure  vs.  Replimune Group

 Performance 
       Timeline  
NextCure 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days NextCure has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
Replimune Group 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Replimune Group has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in April 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

NextCure and Replimune Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with NextCure and Replimune

The main advantage of trading using opposite NextCure and Replimune positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NextCure position performs unexpectedly, Replimune can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Replimune will offset losses from the drop in Replimune's long position.
The idea behind NextCure and Replimune Group pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Other Complementary Tools

Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios